 Triple negative breast cancer, TNBC, is a highly aggressive form of breast cancer with a poor prognosis. Conventional treatments, such as surgery, radiation, and chemotherapy, are often not effective against TNBC, leading to a high mortality rate. Recent advances in single-cell sequencing technologies have allowed researchers to explore the complex and heterogeneous TNBC tumor microenvironment on a cellular level, identifying potential biomarkers for immunotherapies. These biomarkers include PD-L1 expression, TILS, and TMB, which can be used to identify patients who may benefit from immunotherapeutic approaches. This review summarizes the background, motivation, methodology, results, findings, and conclusions of multi-omic studies that have identified these biomarkers, suggesting that they hold great promise for the development of more effective treatments for TNBC patients. This article was authored by Jiang Nanyu, Zhikun Guo, and Lei Wan. We are article.tv, links in the description below.